Prespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Researchers compare relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in patients with platinum-resistant ...

Tired of awareness campaigns that fade? Emily Campbell's "Not These Ovaries" sparks action for faster ovarian cancer ...

Ovarian cancer isn't silent - learn the early warning signs. Persistent bloating, pelvic pain, urinary symptoms revealed.

Relacorilant blocks GR activation, a key pathway driving stress-induced chemoresistance in ovarian cancer cells.

US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

Brian Slomovitz, MD, of Mount Sinai Medical Center, compares relacorilant plus nab-paclitaxel with existing treatments for platinum-resistant ovarian cancer and highlights the ROSELLA trial’s global ...

Survival rates among breast cancer patients whose cancer is detected before it spreads are high, between 86% and 89%. Yet if ...